Application of PKG System for Objective Measurement and Early Identification in Parkinson’s Disease
Objective: This study aimed to assess the correlations of the PKG data with clinical scores of bradykinesia, rigidity and tremor. Background: The treatment of levodopa…A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in De Novo vs Rollover Patients With Parkinson’s Disease: Interim Results
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL-130277; APL) for on-demand treatment of “OFF” episodes in de novo (DN) vs…Phase I Study Design of a Leucine-Rich Repeat Kinase 2 (LRRK2) Antisense Oligonucleotide, for Parkinson’s Disease
Objective: We will present the preclinical efficacy and safety data and the design of the first in human trial of an antisense oligonucleotide (ASO) for…Passive monitored daily motor behavior significantly relates to quality of life in early Parkinson’s disease
Objective: To investigate whether passively acquired measures of gait and hand gestures are associated with health-related quality of life (HrQoL; PDQ-39) and health-state (EQ-5D-5L) in…Spontaneous smoking cessation in a parkinsonian patient treated with apomorphine pump
Objective: To describe the case of a parkinsonian patient treated by apomorphine pump who stopped smoking without difficulty despite being dependent to nicotine. To explore…Efficacy and Safety of Opicapone in Parkinson’s Disease Patients According to Duration of Motor Fluctuations: Post-Hoc Analysis of BIPARK-I and II
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) in levodopa-treated Parkinson’s disease (PD) patients with duration of motor fluctuations of…Monitoring electrophysiological recordings in patients with LCIJ therapy
Objective: Levodopa carbidopa intestinal jel (LCIJ) treatment for advanced Parkinson’s disease patients is live-saving for the appropriate patients, however follow up of the patients has…Correlation Between Dyskinesia and Quality of Life at Baseline and After 12 months of Treatment with LCIG in Patients with Advanced Parkinson’s Disease
Objective: Evaluate the correlation between dyskinesia and quality of life (QoL) at baseline and after 12 months of treatment with levodopa-carbidopa intestinal gel (LCIG) in…New compound increasing glucocerebrosidase activity on primary cell cultures obtained from patients with GBA-associated Parkinson’s disease
Objective: To determine whether new chemical modifications of the previously described allosteric GCase chaperone N607 (Aflaki E et.al Neurosc. 2016) increase GCase activity in monocyte-derived…High levodopa plasma concentration in the acute levodopa challenge test predicts levodopa-induced dyskinesia in Parkinson’s disease
Objective: We aimed to investigate the correlation between levodopa pharmacokinetics and levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD). Background: In patients with PD, pulsatile dopaminergic…
- « Previous Page
- 1
- …
- 122
- 123
- 124
- 125
- 126
- …
- 149
- Next Page »